BOSTON, Oct. 24, 2019 /PRNewswire/ -- Proteostasis
Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical
company dedicated to the discovery and development of
groundbreaking therapies to treat cystic fibrosis (CF) and other
diseases caused by dysfunctional protein processing, today
announced that the Company's cystic fibrosis transmembrane
conductance regulator (CFTR) modulators will be highlighted in five
presentations at the North American Cystic Fibrosis Conference
(NACFC) from October 31 –
November 2, 2019 at the Nashville
Music City Center in Nashville,
Tennessee.
Details for the presentations are as follows:
Title:
|
Initial Results
Evaluating the First in Class CFTR Amplifier, PTI-428, in Subjects
with CF on
|
|
Background Treatment
with Tezacaftor/Ivacaftor
|
Presenter:
|
Jennifer L.
Taylor-Cousar, M.D., M.S.C.S., Associate Professor of
Medicine
|
|
and Pediatrics, and
Co-Director and CF Therapeutics Development Network Director of the
Adult CF
|
|
Program
at National Jewish Health
|
Session
Type:
|
Poster
Presentation
|
Abstract
No:
|
470
|
Date and
time:
|
Thursday, October 31,
2019 from 11:15 a.m.-1:45 p.m. CDT
|
Title:
|
Novel
Amplifier-Enhanced High-Throughput Screen for G542X-CFTR PTC
Suppression
|
|
Identifies
Translational Read-Through Modulators with Different
Profiles
|
Presenter:
|
Danijela Dukovski,
Senior Scientist and Project Lead, Proteostasis
Therapeutics
|
Session
Type:
|
Poster
Presentation
|
Abstract
No:
|
518
|
Date and
time:
|
Thursday, October 31,
2019 from 11:15 a.m.-1:45 p.m. CDT
|
Title:
|
Evaluation of Novel
CFTR Modulator Combinations of the Corrector PTI-801,
Potentiator
|
|
PTI-808, and
Amplifier PTI-428 in CF Subjects
|
Presenter:
|
Patrick Flume, M.D.,
Professor of Medicine and Pediatrics, Medical University of
South
|
|
Carolina
|
Session
Type:
|
Poster
Presentation
|
Abstract
No:
|
511
|
Date and
time:
|
Thursday, October 31,
2019 from 11:15 a.m.-1:45 p.m. CDT
|
|
|
|
|
and
|
|
|
|
Session
Type:
|
Oral
Presentation
|
Session
Title:
|
New & Emerging
Therapies to Correct the Basic Defect
|
Date and
time:
|
Friday, November 1,
2019 from 2:15-3:35 p.m. CDT
|
Title:
|
Current Status of the
Proteostasis Therapeutics CFTR Modulator Development
Program
|
Presenter:
|
Patrick Flume, M.D.,
Professor of Medicine and Pediatrics, Medical University of
South
|
|
Carolina
|
Session
Type:
|
Symposium
Presentation
|
Session
Title:
|
CFTR Modulators:
Current Progress & Future Challenges
|
Date and
time:
|
Friday, November 1,
2019 from 10:30 a.m.-12:15 p.m. CDT
|
For more information on this meeting, visit:
https://www.nacfconference.org/Home/
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage
biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional
protein processing. Headquartered in Boston, MA,
the Proteostasis Therapeutics team focuses on identifying
therapies that restore protein function. For more information,
visit www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as "aim," "may," "will," "expect,"
"anticipate," "estimate," "intend," and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. Examples of forward-looking
statements made in this release include, without limitation,
statements regarding the expected presentations at an upcoming
conference. Forward-looking statements made in this release
involve substantial risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you
that our plans, intentions, expectations or strategies will be
attained or achieved. Such risks and uncertainties include,
without limitation, the potential of our proprietary combination
therapies for the treatment of CF, the potential benefit of our
proprietary combination therapies to patients, expected timing of
patient enrollment in, data from, the completion of, our clinical
studies and cohorts for our clinical programs, including our
planned Phase 2 program and initiation of a pivotal or
registrational study, the possibility final or future results from
our drug candidate trials (including, without limitation, longer
duration studies) do not achieve positive results or are materially
and negatively different from or not indicative of the preliminary
results reported by the Company (noting that these results are
based on a small number of patients and small data set),
uncertainties inherent in the execution and completion of clinical
trials (including, without limitation, the possibility that FDA or
other regulatory agency comments delay, change or do not permit
trial commencement, or intended label, or the FDA or other
regulatory agency requires us to run cohorts sequentially or
conduct additional cohorts or pre-clinical or clinical studies), in
the enrollment of CF patients in our clinical trials in a
competitive clinical environment, in the timing of availability of
trial data, in the results of the clinical trials, in possible
adverse events from our trials, in the actions of regulatory
agencies, in the endorsement, if any, by therapeutic development
arms of CF patient advocacy groups (and the maintenance thereof),
in the commercialization and acceptance of new therapies globally,
and those set forth in our Annual Report on Form 10-K for the year
ended December 31, 2018, our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 and our other SEC filings. We
assume no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
Investors:
David Pitts
/ Claudia Styslinger
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-announces-presentations-highlighting-its-cftr-modulators-at-the-north-american-cystic-fibrosis-conference-300944572.html
SOURCE Proteostasis Therapeutics, Inc.